Introduction
Introduction Statistics Contact Development Disclaimer Help
Return Create A Forum - Home
---------------------------------------------------------
Data Report
https://datareport.createaforum.com
---------------------------------------------------------
*****************************************************
Return to: Covid Treatments
*****************************************************
#Post#: 821--------------------------------------------------
Covid Vaccine for XBB Variants Ready for Clinical Trials - China
By: Steve Date: May 18, 2023, 6:41 pm
---------------------------------------------------------
SUMMARY - WestVac, a Chinese-based pharmaceutical company, has
developed a Covid vaccine made to combat the XBB lineage of the
virus to be ready for clinical trials.
COMMENTARY - Although promising, let us remember that China
(and, by extension, a lot of their companies) is not entirely
transparent with it's information and details concerning a lot
of topics, including Covid-19.
Entering a clinical trial is not synonymous with succeeding in
what the treatment sets out to achieve. A lot of these trials
fail. If every drug or treatment that entered clinical trials
succeeded in what they had wanted to accomplish, we would
already had cured several forms of cancer along with Alzheimer's
& Parkinson's disease by now. This is also not an mRNA-styled
vaccine, such as the ones from Moderna or Pfizer and, given past
history, mRNA-styled vaccines have had the most success in
dealing with the virus.
As in all such cases, let us hope for the best from these
clinical trials but be prepared to keep searching for a more
successful response.
LINK -
https://www.prnewswire.com/news-releases/the-first-of-its-kind-in-the-world-the…
https://www.prnewswire.com/news-releases/the-first-of-its-kind-in-the-world-the…
*****************************************************
You are viewing proxied material from gopher.createaforum.com. The copyright of proxied material belongs to its original authors. Any comments or complaints in relation to proxied material should be directed to the original authors of the content concerned. Please see the disclaimer for more details.